Market Intelligence, Clinical Progress, and High-Purity Reagents for Ferroptosis-Inducing Cancer Therapy and Metabolic Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ACSL4/FACL4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ACSL4/FACL4 Recombinant Enzyme High purity (>95%), Endotoxin <1EU/ug, E. coli or HEK293 expressed. Sequence Verified. ATP-binding domain intact. |
View ACSL4 Products |
| Gene Delivery | ACSL4/FACL4 ORF Lentivirus Full-length ORF for stable overexpression in cancer cell lines. |
View ACSL4 Products |
| Benchmark Ab | Anti-ACSL4 (Clone Reference Standard) Recombinant rabbit monoclonal for Western/IP and pull-down. Sequence-verified positive control. |
View ACSL4 Products |
| Validator | ACSL4/FACL4 siRNA Set For knockdown verification and ferroptosis rescue assays. |
View ACSL4 Products |
| Paralog Selectivity | ACSL3 Close paralog for counter-screening to ensure isoform specificity. |
View ACSL3 Products |
| Pathway Partner | GPX4 Ferroptosis execution enzyme; synergistic target for combination studies. |
View GPX4 Products |
| Resistance Node | SLC7A11 (xCT) Cystine transporter; ferroptosis resistance mechanism. |
View SLC7A11 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform & Subfamily Selectivity (ACSL3 vs ACSL4; ACSL1/3/5) | High-purity ACSL4/1/3/5 homolog proteins (>95% purity) strictly verified by mass spectrometry and sequence analysis, available as orthogonal pair for paralog screening. |
| Enzymatic Activity Quantification & Preservation | Sequence-verified ATP/AMP binding domains; Theoretical MW confirmed by SDS-PAGE; Recombinant proteins optimized for functional integrity. |
| Ferroptosis Rescue Validation & Reliable Controls | Validated siRNA sets for specificity control in lipid peroxidation assays; Sequence-verified validation antibodies for consistent Western Blot and Target Engagement. |
| False Positives & Membrane Permeability | Endotoxin-controlled (<1EU/ug) reagents and high-concentration protein stability validated for cellular uptake studies. |
Live ACSL4/FACL4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ACSL4/FACL4 therapeutics is intensifying, with major players shifting focus from traditional cytotoxic agents to metabolic disruption via ferroptosis induction. As first-generation ferroptosis inducers reach preclinical milestones, the next wave of R&D is targeting selective ACSL4 inhibition to spare normal tissues while exploiting lipid peroxidation vulnerabilities in cancer. Additionally, ACSL4's role as a central executioner of ferroptosis makes it therapeutically actionable for both inducing ferroptosis in therapy-resistant solid tumors and inhibiting it to prevent ischemia-reperfusion injury. The pipeline includes small molecule inhibitors, PROTACs, agonists, and gene therapy approaches across oncology, neurodegeneration, and acute kidney injury.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Emerging academic biotechs, Metabolic-focused startups | Triple-negative breast cancer, Renal cell carcinoma, Ischemia, Neurodegeneration | Enzymatic Activity Assay & Selectivity Assay (Need high-purity recombinant ACSL4 with active ATP-binding site and ACSL subfamily proteins) |
| PROTAC Degraders | Targeted protein degradation companies, Early Stage Innovators | Drug-resistant tumors, Therapy-resistant solid tumors | Cell-based Degradation & Target Engagement (Need validated siRNA controls, overexpression lentivirus, and sequence-verified cellular antibodies) |
| Agonists / Ferroptosis Inducers | Oncology Pipelines | Hepatocellular carcinoma, Breast cancer | Enzymatic Assay (Need active recombinant enzyme with high purity) |
| Combination (Immunotherapy) | IO + Metabolic modulation players | Immunotherapy-resistant cancers | Pathway Crosstalk (Need GPX4/SLC7A11 panel for combination screening) |
| Gene Therapy / siRNA | Preclinical Discovery | Acute Kidney Injury | Knockdown Validation (Need high-efficiency lentivirus & siRNA) |